A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects

NCT03935568 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

40

Enrollment

INDUSTRY

Sponsor class

Stopped Company ceased operations

Conditions

Alzheimer's Disease

Interventions

DRUG: PU-AD
DRUG: Placebo
DRUG: Placebo
DRUG: PU-AD

Sponsor

Samus Therapeutics, Inc.